Sorry to repeat the extract from Wengers post, the reason that I have is to give you all an indication of the potential market share that GW will be competing for when the licence is granted for arthritis.
Extract from Wengers post he seems to get it right more often than not,
"GW closed on the first trading day of 2005 at 118.5p. With luck it'll match that on the last trading day of 2005. GW has made huge net progress since 4/1/05. It has a great new partner. It has plenty of cash. It is near to completing the Phase III trial that will guarantee MHRA approval (and I do mean guarantee). It may be close to an IND. It has great data on rheumatoid arthritis palliation (maybe even a cure), but it's worth no more than a nearly year ago."
I have great hopes for GW. The best of luck and a Happy New Year to all of us.
Introduction
The global Rheumatoid Arthritis (RA) market has experienced extraordinary growth over the last decade. This market valued at $4.14 billion in 2004, shows no hint of decline. The explosion in new disease modifying drugs since the late 1990's has resulted in a competitive and rapidly evolving market. However, the recent events in the COX-2 market will continue to impact all arthritis drugs.
A question for the experts here, instead of a Sativex spray why not dispense by jell under the tongue.
Happy new year to all regards E.
GW Pharm stock quotes
GW Pharm stock charts
Follow this thread
